

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### The effect of quercetin supplementation on liver enzymes, inflammation indices, lipid profile and body composition, accompanied by color control in nonalcoholic fatty liver disease: A randomized, double-blind, pilot study

#### Protocol summary

##### Summary

This study aimed to evaluate the effects of quercetin supplementation on the lipid profile, liver enzymes, inflammatory markers and body composition in non alcoholic fatty liver disease. Inclusion criteria included: Failure to alcohol abuse; Body mass index equal to or greater than 25-40 Kg / m<sup>2</sup>; Lack of other acute and chronic liver diseases and disorders; No history of biliary tract disease in the past; Lack of acute heart disease, inherited disorders affecting liver condition and Exclusion criteria: Not wanting to continue working, diseases that require special treatment, Reduction of more than 10% of baseline body weight during the intervention period, not consumption of more than 10% of the supplements in any follow-up period and in general, any inconsistent with the inclusion criteria. This study will be conducted on 110 men and women with nonalcoholic fatty liver disease, in two supplement and placebo groups confirmed by ultrasound. Intervention patients, receive 500mg capsule supplement daily, morning and evening on an empty stomach, while the placebo group received placebo twice daily 500mg capsule that looks like the original supplements. anthropometric Data collection (weight, height, body mass index, etc.) and body composition analysis using the bioelectrical impedance analysis will be measured four times during the study. 10 ml of venous blood will be taken of people at the beginning and end of the study in fasting. Measuring lipid profile variables and liver enzymes by enzymatic methods and inflammatory markers such as: tumor necrosis factor alpha and c-reactive protein also will be measured using ELISA method.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2016060628299N1**

Registration date: **2016-07-13, 1395/04/23**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2016-07-13, 1395/04/23

##### Registrant information

###### Name

Mahboobe Hosseinikia

###### Name of organization / entity

Kermanshah University of Medical Sciences, School of Public Health

###### Country

Iran (Islamic Republic of)

###### Phone

+98 83 3424 3452

###### Email address

m.hoseinikia@kums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

The cost of the project was paid entirely from the budget of Kermanshah University of Medical Sciences

##### Expected recruitment start date

2016-07-10, 1395/04/20

##### Expected recruitment end date

2016-09-22, 1395/07/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

**Scientific title**

The effect of quercetin supplementation on liver enzymes, inflammation indices, lipid profile and body composition, accompanied by color control in nonalcoholic fatty liver disease: A randomized, double-blind, pilot study

**Public title**

The effect of quercetin supplementation on nonalcoholic fatty liver disease

**Purpose**

Supportive

**Inclusion/Exclusion criteria**

Inclusion criteria include: a willingness to participate; age 18-65 years; non-alcoholic fatty liver diagnosed by ultrasonography and liver function tests (Alanine transaminase and Aspartate transaminase (more than 30u/l in men and more than 20u/l in women)); Lack of alcohol abuse (taking more than 10 grams per day for women and more than 30 grams per day for men); Body mass index equal to or greater than 40Kg/M<sup>2</sup>; Lack of other acute and chronic liver disorders (hepatitis B and C, etc.); Wilson's disease; cirrhosis; no history of biliary tract disease; acute heart failure disease; renal; pulmonary; infectious diseases; diabetes; cancer; inherited disorders affecting liver condition (iron storage disease, etc.); the absence of pregnancy and lactation; disease related to thyroid disorders; No history of weight loss surgery in the past year; the absence of weight loss in the past three months and in general, lack of increase or decrease in weight regimes during the three months prior to sampling; Autoimmune diseases such as primary biliary cirrhosis, autoimmune hepatitis, sclerosing cholangitis; Non-use of antioxidant supplements during one month prior to sampling; Lack of use of effective drugs against weight during the three months prior to sampling; Do not use multivitamin-minerals and drugs that are most likely associated with this disease (Antiepileptic drugs, amiodarone, corticosteroids, phenytoin, lithium, roacutan, tamoxifen, methotrexate, aspirin, 5-fluorouracil, zidovudine, a synthetic estrogen, inhibitors of hydroxymethyl glutaryl coa reductase and etc.); Lack of exposure to pesticides and insecticides such as: carbon tetrachloride; trichloroethylene; Avoiding the use of drugs that are likely to overlap with quercetin; including anticoagulants, inhibitors of CYP3A4 and ....

Exclusion criteria included: Not wanting to continue working; diseases that require special treatment; Reduction of more than 10% of baseline body weight during the intervention period; not consumption of more than 10% of the supplements in any follow-up period and in general, any inconsistent with the inclusion criteria

**Age**

From **18 years** old to **65 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **110**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Kermanshah University of Medical Sciences

**Street address**

Building No. 2, Shahid Beheshti Boulevard,  
Kermanshah

**City**

Kermanshah

**Postal code****Approval date**

2010-08-20, 1389/05/29

**Ethics committee reference number**

KUMS.REC.2016.79

**Health conditions studied****1****Description of health condition studied**

Non Alcoholic Fatty Liver Disease

**ICD-10 code**

K76.0

**ICD-10 code description**

Fatty (change of) liver, not elsewhere classified

**Primary outcomes****1****Description**

Lipid profile

**Timepoint**

at first and the end of study

**Method of measurement**

enzymatic method

**2****Description**

liver enzymes

**Timepoint**

at first and the end of study

## Method of measurement

enzymathic method

### 3

#### Description

inflammatory markers

#### Timepoint

at first and the end of study

#### Method of measurement

ELISA method

## Secondary outcomes

### 1

#### Description

body composition

#### Timepoint

at first of the study and the end of forth,eighth and Twelfth weeks

#### Method of measurement

BIA

### 2

#### Description

weight

#### Timepoint

at first of the study and the end of forth,eighth and Twelfth weeks

#### Method of measurement

With light clothing and using Seca scales with 100 gAccuracy

### 3

#### Description

height

#### Timepoint

Accuracy

#### Method of measurement

بدون کفش با استفاده از قد سنج سکا با دقت 0.1 سانتی متر

### 4

#### Description

Waist circumference

#### Timepoint

at first of the study and the end of forth,eighth and Twelfth weeks

#### Method of measurement

Using a tape measure between the lowest gear and iliac crest with accuracy of 0.5 cm

### 5

#### Description

Hip circumference.

#### Timepoint

at first of the study and the end of forth,eighth and Twelfth weeks

#### Method of measurement

Using a tape measure at the biggest part of the hips

## Intervention groups

### 1

#### Description

Sigma quercetin supplements, 500 mg per day for 55 people in the intervention group for three months,Be taken on an empty stomach

#### Category

Treatment - Drugs

### 2

#### Description

placebo supplement containing starch but looks completely like the original supplementation for placebo group received 500 mg per day for 55 people for three months,Be taken on an empty stomach

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Dr.Nawabi Clinic

##### Full name of responsible person

Mahboobe Hosseibikia

##### Street address

Ejlaliye Building ,municipalStreet, Kermanshah

##### City

Kermanshah

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Kermanshah University of Medical Sciences

##### Full name of responsible person

Dr.Berooz Hamzeh

##### Street address

Building No. 2, Shahid Beheshti Boulevard, Kermanshah

##### City

Kermanshah

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Kermanshah University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

empty

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

Kermanshah

**Postal code****Phone**

+98 83 3826 2005

**Fax****Email**

yahya.pasdar@kums.ac.ir

**Web page address****Person responsible for general inquiries****Contact****Name of organization / entity**

Kermanshah University of Medical Sciences, School of Public Health

**Full name of responsible person**

Mahboobe Hosseinikia

**Position**

MSc Student in nutritional Sciences

**Other areas of specialty/work****Street address**

Faculty of Health, ISAR Field next to Farabi Hospital

**City**

Kermanshah

**Postal code****Phone**

+98 83 3422 1215

**Fax****Email**

M.hosseinikia@yahoo.com

**Web page address****Person responsible for updating data****Contact****Name of organization / entity**

Kermanshah University of Medical Sciences, School of Public Health

**Full name of responsible person**

Mahboobe Hosseinikia

**Position**

MSc Student in nutritional Sciences

**Other areas of specialty/work****Street address**

Faculty of Health, ISAR Field next to Farabi Hospital

**City**

Kermanshah

**Postal code****Phone**

00

**Fax****Email****Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Faculty of Health, ISAR Field next to Farabi Hospital, Kermanshah University of Medical Sciences

**Full name of responsible person**

Yahya Pasdar

**Position**

PhD in Nutrition Sciences

**Other areas of specialty/work****Street address**

Faculty of Health, ISAR Field next to Farabi Hospital

**City****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*